July 12th, 2016. 10.30 Reaching coverage and universal access for expensive drugs and medical devices in Chile ❖ Implementing HTA with a new focus. ❖ Balancing slow decision-making with the need for rapid patient access and transparency? ❖ Finding value on a bad CEAs result.:What can the pharmaceutical industry do to satisfy payer needs? ❖ Gathering real-world data to evaluate the impact of technology incorporation. Dr. Andrea Basagoitia Chief of Studies and HTA Institute of Public Health, Chile